Clinical trials: Gram-Negative Bacteria
Multi-resistant Gram-negative Bacteria Cause Infection
To Evaluate the Pharmacokinetics and Safety of TQD3524 for Injection in Renal Impairment Subjects
This is an open, open-label, parallel, single-dose, phase I clinical study designed to evaluate the pharmacokinetic (PK) profile of TQD3524 injection in patients with renal impairment after a single dose, and to evaluate the…
- Trial name
- NCT06522945
- Testing
- TQD3524
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Urinary Tract Infections, Enterobacteriaceae Infections
Piperacillin/Tazobactam Versus Carbapenems in Non-bacteremic UTI Due to -ESBL-producing Enterobacteriaceae
This study evaluates the efficacy in achieving clinical cure in non-bacteremic urinary tract infections (UTI) caused by Escherichia coli or Klebsiella pneumoniae producers of extended-spectrum β-lactamases (ESBL) in adult…
- Conditions
- Urinary Tract Infections, Enterobacteriaceae Infections, Infection Due to ESBL Bacteria, Carbapenem
- Trial name
- CAPITIS (NCT03891433)
- Testing
- Meropenem, Ertapenem 1000 MG, Piperacillin, Tazobactam 4-0.5G Solution for Injection
- Where
- Colombia
- Volunteers
- 198 people
- Sponsor
- Universidad del Norte
Bacterial Pneumonia
Comparative Study of Ceftaroline vs. Ceftriaxone in Adult Subjects With Community-Acquired Pneumonia
The purpose of this study is to determine whether ceftaroline is effective and safe in the treatment of Community-Acquired Pneumonia
- Trial name
- CAP (NCT00621504)
- Testing
- Ceftaroline fosamil for Injection, IV Ceftriaxone, Clarithromycin
- Where
- 168 sites in United States, Argentina and 21 more
- Volunteers
- 606 people
- Sponsor
- Forest Laboratories
Gram Negative Infections, Sepsis and Septic Shock
A Combination Therapy With Ceftazidime and Fosfomycin Will be Compared to Ceftazidime Alone in Hospitalized Adult Patients With Suspected Severe Gram-negative Bacterial Infections
The goal of this clinical trial is to : 1. Test whether the combination of CAZ±AVI and FOS leads to superior clinical outcomes in patients with severe suspected Gram-negative bacterial infection, as demonstrated by a shorter time…
- Trial name
- CAVIFOS (NCT07063095)
- Testing
- Ceftazidime± avibactam with fosfomycin
- Where
- Switzerland
- Volunteers
- 100 people
- Sponsor
- Angela HUTTNER
Bone and Joint Prosthetic Infections
BJI Inoplex 2 : Test for Diagnosis of Prosthetic Infections
A national, prospective, open-label, non-interventional, multicentre, controlled study designed to evaluate a diagnostic method in patients undergoing hip, knee or shoulder prosthetic removal regardless of whether or not…
- Trial name
- NCT02222792
- Where
- 2 sites in France
- Volunteers
- 540 people
- Sponsor
- Diaxonhit
Healthy
Study to Determine and Compare Plasma and Intrapulmonary Concentrations of ETX2514 and Sulbactam in Healthy Subjects
This is a Phase 1, multiple dose, open-label pharmacokinetic study conducted in healthy adult male and female subjects to determine and compare plasma, epithelial lining fluid (ELF) and alveolar macrophage (AM) concentrations of…
- Trial name
- NCT03303924
- Testing
- ETX2514 and sulbactam
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Entasis Therapeutics
Bronchiectasis
Evaluation of the Quality of Life Questionnaire-Bronchiectasis (QOL-B) in Patients With Bronchiectasis
Over the 70-day study period, eligible patients visited the study clinic every 2 weeks (total of 6 visits) and received a 28-day course of aztreonam for inhalation solution (AZLI).
- Trial name
- NCT00805025
- Testing
- AZLI
- Where
- 24 sites in United States
- Volunteers
- 89 people
- Sponsor
- Gilead Sciences
Gram-negative Bacteria
Population Pharmacokinetic Study of Colistin in Patients Infected With Multiresistant Gram-negative Bacteria
Nosocomial infections have become a major health problem. They induced important use of antibiotics which is a preponderant factor for the development of bacterial resistance.
- Trial name
- NCT01060891
- Testing
- colimycin
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Poitiers University Hospital
Allogeneic or Autologous HSCT
Gram-negative Bacteremia in HSCT Recipients
A significant increase in resistant bacteria emerging in HSCT recipients. For example, 25% - 42% of all enterobacteriaceae produce extended spectrum beta-lactamases; 8 - 72% of Pseudomonas aeruginosa are resistant to at least one…
- Trial name
- GNB (NCT02257931)
- Where
- 10 sites in Belgium, China and 7 more
- Volunteers
- 591 people
- Sponsor
- European Society for Blood and Marrow Transplantation
Hospital-acquired Bacterial Pneumonia/Ventilator-associated Bacterial Pneumonia
Study on the Safety and Efficacy of Polymyxin E2 Methanesulfonate for Injection in the Treatment of Hospital-Acquired Bacterial Pneumonia/Ventilator-Associated Bacterial Pneumonia Caused by Carbapenem-Resistant Gram-Negative Bacteria
Study on the Safety and Efficacy of Polymyxin E2 Methanesulfonate for Injection in the Treatment of Hospital-Acquired Bacterial Pneumonia/Ventilator-Associated Bacterial Pneumonia Caused by Carbapenem-Resistant Gram-Negative…
- Trial name
- NCT07512596
- Testing
- TQD3524, Meropenem for injection, Colistimethate Sodium for Injection
- Where
- 27 sites in China
- Volunteers
- 48 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Gram-negative Bacteraemia
Early Oral Switch for Uncomplicated Gram-negative Bacteraemia
Current management of uncomplicated Gram-negative bacteraemia entails prolong intravenous (IV) antibiotic therapy with limited evidence to guide oral conversion.
- Trial name
- INVEST (NCT05199324)
- Testing
- Oral fluoroquinolones (most commonly, ciprofloxacin) or oral trimethoprim-sulfamethoxazole, Standard of care intravenous antibiotics (e.g. ceftriaxone, cefazolin)
- Where
- 25 sites in Australia, Greece and 9 more
- Volunteers
- 720 people
- Sponsor
- Tan Tock Seng Hospital
Nosocomial Infections
Effect of Metallic Nanoparticles on Nosocomial Bacteria
This research aims to study the properties of metallic nanoparticles"MNPs" (silver nanoparticles "AgNps" and copper nanoparticles "CuNps") on the 2 most common nosocomial bacteria which are highly resistant to antibiotics…
- Trial name
- NCT04775238
- Testing
- Silver nanoparticles, Copper nanoparticles
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Sohag University
Psuedomas Infection, Cystic Fibrosis
The Role of Bacteria and Genetic Variations in Cystic Fibrosis
This study will examine 1) the role of hereditary factors in cystic fibrosis; i.e., the relationship of the disease to specific gene variations, and 2) the role of bacterial products involved in lung infections substances…
- Trial name
- NCT00043225
- Where
- 4 sites in United States
- Volunteers
- 76 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Multi-antibiotic Resistance
Use of New Antibiotics in Sweden
Antibiotic resistance is a growing global health problem of great concern, especially multidrug-resistant Gram-negative bacteria. In recent years some new antibiotics targeting these bacteria have been developed.
- Trial name
- NCT05048693
- Where
- 7 sites in Sweden
- Volunteers
- 41 people
- Sponsor
- Uppsala University
Probiotics, Enterobacteriaceae Infections
Prevention and Decolonization of Multidrug-resistant Bacteria With Probiotics
This study explores the effect of probiotic administration to decrease colonization by Carbapenem resistant Enterobacteriaceae (CRE) in at-risk populations.
- Trial name
- NCT03967301
- Testing
- Probiotic
- Volunteers
- 228 people
- Sponsor
- Hospital Italiano de Buenos Aires
Neutropenia
Mouthwash With Chlorhexidine 0.12%/Ethyl Alcohol 7% Compared to Ethyl Alcohol 7%
Clinical triple-blind randomized controlled trial to assess the use of two different mouthwashes to reduce the oral colonization by gramnegative bacteria in patients with chemotherapy
- Trial name
- NCT02414581
- Testing
- chlorhexidine 0.12%/Ethyl alcohol 7%, Ethyl Alcohol 7%, Chlorhexidine 2%/Ethyl alcohol 7%
- Where
- Mexico
- Volunteers
- 60 people
- Sponsor
- Hospital Regional de Alta Especialidad del Bajio
Urinary Tract Infections, Urosepsis
Prevalence of Antimicrobial-resistant Pathogens in Patients Admitted for UTIs
Between 2013-2014, our study network of U.S. emergency departments, EMERGEncy ID NET, found that the rate of fluoroquinolone-resistant E. coli was 11.7% among all patients, 6.3% in uncomplicated and 19.9% in complicated.
- Trial name
- NCT03346603
- Testing
- urine culture and susceptibility testing
- Where
- United States
- Volunteers
- 801 people
- Sponsor
- Olive View-UCLA Education & Research Institute
Gram-Negative Bacterial Infections
A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Minocin® (Minocycline) for Infections Caused by Gram-negative Bacteria in a Real World Setting
This study is a retrospective, observational study to evaluate minocycline use in participants under real world conditions.
- Trial name
- NCT03160040
- Testing
- Minocycline IV
- Where
- 6 sites in United States
- Volunteers
- 71 people
- Sponsor
- Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)
Pneumonia
Nebulized Colistin for Hospital-Acquired Pneumonia
Nebulized Colistin for Adjunctive Therapy of Hospital-Acquired Pneumonia caused by Gram Negative Bacteria should be more effective than conventional therapy
- Trial name
- NCT00920270
- Testing
- nebulized colistin, antibiotics
- Where
- Thailand
- Volunteers
- 140 people
- Sponsor
- Mahidol University
Bacterial Growth, Novel Influenza A (H1N1)
The Research of Novel Electrolyzed Water Spray to Eradicate Bacteria E-coli and an Attenuated Human Flu Virus
The purpose of this study is to test whether spraying the hand of patients by use of the novel electrolyzed water spray will decrease the number of bacteria E-coli and the virus titer of an attenuated human flu virus.
- Trial name
- NCT05797103
- Testing
- A novel electrolyzed water spray reduces numbers of bacteria E-coli and an attenuated human flu virus on human hands
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Dove Medical Press Ltd